Q2 2024 EPS Estimates for TransMedics Group, Inc. (NASDAQ:TMDX) Lifted by William Blair

TransMedics Group, Inc. (NASDAQ:TMDX) – Analysts at William Blair increased their Q2 2024 earnings per share (EPS) estimates for TransMedics Group in a research note issued on Tuesday, April 30th. William Blair analyst R. Daniels now forecasts that the company will earn $0.10 per share for the quarter, up from their previous forecast of ($0.11). The consensus estimate for TransMedics Group’s current full-year earnings is $0.54 per share. William Blair also issued estimates for TransMedics Group’s Q3 2024 earnings at ($0.06) EPS, Q4 2024 earnings at ($0.15) EPS, FY2024 earnings at $0.23 EPS, Q1 2025 earnings at ($0.12) EPS, Q2 2025 earnings at ($0.02) EPS and Q4 2025 earnings at $0.28 EPS.

TransMedics Group (NASDAQ:TMDX) last announced its earnings results on Tuesday, April 30th. The company reported $0.35 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.05) by $0.40. The firm had revenue of $96.90 million during the quarter, compared to analyst estimates of $83.78 million. TransMedics Group had a positive return on equity of 8.29% and a negative net margin of 3.43%. The business’s revenue was up 132.9% compared to the same quarter last year. During the same period last year, the firm posted ($0.08) EPS.

TMDX has been the subject of a number of other reports. TD Cowen increased their target price on shares of TransMedics Group from $100.00 to $130.00 and gave the company a “buy” rating in a research report on Wednesday. Morgan Stanley raised their target price on TransMedics Group from $75.00 to $95.00 and gave the stock an “equal weight” rating in a research report on Wednesday, February 28th. Oppenheimer upped their price target on TransMedics Group from $105.00 to $125.00 and gave the company an “outperform” rating in a research report on Wednesday. Canaccord Genuity Group lifted their price objective on TransMedics Group from $102.00 to $117.00 and gave the stock a “buy” rating in a report on Wednesday. Finally, JPMorgan Chase & Co. upped their price objective on shares of TransMedics Group from $105.00 to $127.00 and gave the company an “overweight” rating in a report on Wednesday. One research analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. Based on data from MarketBeat, TransMedics Group has an average rating of “Moderate Buy” and a consensus target price of $119.00.

TransMedics Group Stock Performance

NASDAQ TMDX opened at $127.99 on Friday. The company has a market capitalization of $4.19 billion, a PE ratio of -376.44 and a beta of 1.87. The company has a debt-to-equity ratio of 3.69, a quick ratio of 8.49 and a current ratio of 9.30. TransMedics Group has a 52-week low of $36.42 and a 52-week high of $129.66. The company has a 50-day simple moving average of $85.54 and a 200 day simple moving average of $77.08.

Institutional Investors Weigh In On TransMedics Group

Institutional investors and hedge funds have recently bought and sold shares of the stock. J.W. Cole Advisors Inc. bought a new position in shares of TransMedics Group in the 3rd quarter worth $929,000. Bank of New York Mellon Corp lifted its stake in TransMedics Group by 91.4% during the third quarter. Bank of New York Mellon Corp now owns 760,099 shares of the company’s stock worth $41,615,000 after purchasing an additional 363,012 shares during the last quarter. Shariaportfolio Inc. purchased a new position in shares of TransMedics Group in the 3rd quarter worth about $470,000. Zurcher Kantonalbank Zurich Cantonalbank increased its position in shares of TransMedics Group by 12.4% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,913 shares of the company’s stock valued at $378,000 after purchasing an additional 763 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. raised its holdings in shares of TransMedics Group by 12.8% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 14,940 shares of the company’s stock valued at $818,000 after buying an additional 1,700 shares in the last quarter. 99.67% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at TransMedics Group

In related news, CEO Waleed H. Hassanein sold 56,000 shares of the business’s stock in a transaction that occurred on Wednesday, May 1st. The shares were sold at an average price of $115.63, for a total transaction of $6,475,280.00. Following the completion of the transaction, the chief executive officer now owns 74,087 shares of the company’s stock, valued at $8,566,679.81. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. In other TransMedics Group news, insider Tamer I. Khayal sold 736 shares of the firm’s stock in a transaction dated Wednesday, February 7th. The stock was sold at an average price of $90.09, for a total value of $66,306.24. Following the sale, the insider now owns 14,375 shares of the company’s stock, valued at approximately $1,295,043.75. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO Waleed H. Hassanein sold 56,000 shares of TransMedics Group stock in a transaction dated Wednesday, May 1st. The shares were sold at an average price of $115.63, for a total value of $6,475,280.00. Following the sale, the chief executive officer now owns 74,087 shares of the company’s stock, valued at approximately $8,566,679.81. The disclosure for this sale can be found here. Insiders sold 236,378 shares of company stock valued at $23,633,449 in the last quarter. 7.00% of the stock is currently owned by corporate insiders.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.